Physician profile
Emily E Schulman
NPI 1891158085
$2,193.17
in general payments reported to CMS, 2019-2025
22 companies · $43.43 in 2025
The $43.43 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.57 · 2022: $155 · 2023: $917 · 2024: $1,053 · 2025: $43.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,013.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $562.08 | 2023-2024 | Qulipta, Botox, Ubrelvy |
| Lilly USA, LLC | $379.24 | 2022-2025 | Kisunla, Amyvid, Emgality |
| Teva Pharmaceuticals USA, INC. | $241.01 | 2022-2024 | Austedo Xr, Ajovy, Austedo |
| Eisai INC. | $196.66 | 2022-2024 | |
| Lundbeck LLC | $138.56 | 2023-2024 | Vyepti |
| Impel Pharmaceuticals INC. | $112.21 | 2023 | Trudhesa |
| Genentech USA, INC. | $69.07 | 2023-2024 | Ocrevus, Ocrevus Zunovo, Evrysdi |
| Pfizer INC. | $62.28 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.50 | 2023 | Gammagard |
| Emd Serono, INC. | $47.47 | 2023-2024 | Mavenclad |
| Neurocrine Biosciences, INC. | $47.08 | 2023-2024 | Ingrezza, Ongentys |
| Biohaven Pharmaceutical Holding Company LTD. | $39.82 | 2022 | |
| Avanir Pharmaceuticals, INC. | $38.91 | 2021-2022 | |
| Sk Life Science, INC. | $32.54 | 2024 | |
| Amgen INC. | $27.43 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Banner Life Sciences, LLC | $23.57 | 2024 | |
| Scilex Pharmaceuticals INC. | $22.56 | 2023 | Ztlido |
| Alnylam Pharmaceuticals INC. | $22.15 | 2024 | Amvuttra |
| Vanda Pharmaceuticals INC. | $21.73 | 2024 | Ponvory |
| Kyowa Kirin, INC. | $19.50 | 2024 | Nourianz |
| Amneal Pharmaceuticals LLC | $19.23 | 2023 | Rytary |
| Biogen, INC. | $14.57 | 2023 | Vumerity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Schulman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.